eight

[키워드] 95% CI accelerated acute respiratory syndrome Adverse reaction age antibody assigned BBIBP-CorV Beijing Block randomisation center China city Cohort concealed Control coronavirus COVID-19 pandemic creation District dose double-blind drug effort eight enrolled Fever geometric mean titre greater group Group allocation groups healthy humans Humoral response IgM/IgG inactivated Infectious diseases investigators Major Mild moderate neutralising antibody response neutralising antibody titre New Older outcome assessors participant Participants Placebo placebo-controlled plan post vaccination prevention Primary outcome Program randomised Randomly receive recipient recipients Registered reported Safe Safety SARS-CoV-2 SARS-CoV-2 vaccine Science secondary outcome separated Serious Adverse Event severity Shangqiu significantly stratified technology tested the placebo group the vaccine Tolerability Trial Vaccine vaccine candidate vaccine candidates
[DOI] 10.1016/S1473-3099(20)30831-8 PMC 바로가기 [Article Type] Clinical Trial